Verastem Oncology to Report Third Quarter 2026 Financial Results on November 5, 2026

BOSTON–(BUSINESS WIRE)–Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its third quarter 2026 financial results and business updates on Thursday, November 5, 2026, at 4:30 pm ET. A live audio webcast of the call, along with accompanying slides, will be available under “Events & Presentations” in the Invest

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.